{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:pde5-inhibitors-for-pulmonary-hypertension",
  "owner": "cardio",
  "kind": "drug",
  "slug": "pde5-inhibitors-for-pulmonary-hypertension",
  "name": "PDE5 inhibitors for pulmonary hypertension",
  "aliases": [
    "Phosphodiesterase 5 Inhibitor",
    "Phosphodiesterase 5 Inhibitors",
    "PDE5 inhibitors",
    "PDE-5 inhibitors",
    "Phosphodiesterase Type 5 Inhibitors"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "PDE5 inhibitors are medicines that block phosphodiesterase type 5, an enzyme that breaks down a signalling molecule called cGMP. The US labels of Revatio (sildenafil) and Adcirca (tadalafil) each call the product a PDE5 inhibitor indicated for the treatment of pulmonary arterial hypertension. Both labels describe the medicine as raising cGMP in the smooth muscle cells of the blood vessels of the lungs, which relaxes them. This class page covers the use for pulmonary arterial hypertension only; the same ingredients have other labels that are not covered here.",
  "summary_technical": "Class page, scoped to the pulmonary arterial hypertension labels of the medicines. MeSH descriptor D058986 (Phosphodiesterase 5 Inhibitors, lastUpdated 2020-05-27) is a broad match: its scope note says the compounds specifically inhibit phosphodiesterase 5, and the descriptor is not limited to pulmonary hypertension. RxClass lists the established pharmacologic class on US drug labels Phosphodiesterase 5 Inhibitor for sildenafil and for tadalafil (read 2026-11-18). The labels read are Revatio (NDA203109, NDA022473, NDA021845; effective 2024-12-18) and Adcirca (NDA022332; effective 2025-12-15). Labels of the same ingredients for other uses were not read. No trial result, dose or instruction is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": "2027-05-18",
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D058986",
      "normalized_value": "D058986",
      "match": "broad",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": "Phosphodiesterase 5 Inhibitors",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "The Adcirca label says tadalafil is an inhibitor of phosphodiesterase type 5, the enzyme responsible for the degradation of cGMP; the Revatio label says sildenafil inhibits cGMP specific PDE-5 in the smooth muscle of the pulmonary vasculature."
  },
  "content_digest": "bf8ea453ea8d5a3210c066b2733c9dafc01d75c5297568ec3a7cb38df6aaa1b4",
  "review": {
    "content_digest": "bf8ea453ea8d5a3210c066b2733c9dafc01d75c5297568ec3a7cb38df6aaa1b4",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The Revatio and Adcirca labels list pulmonary arterial hypertension as the indication",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Pulmonary arterial hypertension is one type of pulmonary hypertension",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:pulmonary-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:sildenafil",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-136411-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:tadalafil",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-358263-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/pde5-inhibitors-for-pulmonary-hypertension/",
  "context_path": "api/v1/context/cardio--pde5-inhibitors-for-pulmonary-hypertension.md"
}
